Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mirogabalin

Daiichi Sankyo logo

NICE recommends Daiichi Sankyo’s Lixiana for DVT and PE

Institute's final guidance concludes the novel oral anticoagulant is cost effective

Daiichi Sankyo logo

Daiichi’s new anticoagulant recommended by NICE

Lixiana nears NHS funding approval for certain patients with atrial fibrillation

Novartis building

Novartis buys chronic pain specialist Spinifex Pharma

Pays $200m for the Australian pharmaceutical company

Daiichi Sankyo logo

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

Japanese firm’s latest product faces tough competition from a fierce NOAC market

Daiichi Sankyo logo

Daiichi Sankyo offloads stake in India’s Sun Pharma

Japanese firm wants to shed its share of the generic Indian drugmaker

Daiichi Sankyo logo

Daiichi Sankyo pays $39m in whistleblower case

Accused of paying US doctors to prescribe its drugs

Daiichi Sankyo logo

Daiichi’s novel anticoagulant Savaysa cleared in US

Approval comes more than three years after it was approved in Japan

- PMLiVE

GSK squares up to Merck with shingles vaccine data

Trial shows vaccine cut the risk of shingles in over 50s by 97%

- PMLiVE

UCB partners with Daiichi to bring epilepsy drug to Japan

Companies partner on expanding market for Vimpat

Daiichi Sankyo logo

Japan’s Daiichi Sankyo pays $410m for Ambit Biosciences

Gains rights to cancer drug quizartinib

- PMLiVE

Japanese product news in brief

Home launch for Astellas' Xtandi, GSK files COPD drug for approval and more

- PMLiVE

European prescribing of new anticoagulants on the increase

Daiichi Sankyo-backed study shows doctors are turning to new drugs for VTE

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links